FDA said to clear updated COVID shots as early as Friday
hapabapa
The U.S. Food and Drug Administration (FDA) is set to authorize the latest versions of COVID-19 vaccines as early as Friday, NBC News reported, citing four people familiar with the plans.
According to sources, the timeline is not finalized and is subject to change. Two sources said that the FDA is evaluating the potential of issuing full approval instead of an emergency use authorization, a move the agency didn't follow in previous clearances of COVID shots.
After the FDA's decision, the Centers for Disease Control and Prevention (CDC) must sign off on the shots for immunizations to begin.
The CDC's Advisory Committee on Immunization Practices (ACIP) is expected to vote on the vaccines at a meeting on Sept. 12.
CDC advisory committees issue non-binding recommendations. However, the federal agency usually follows them before making a final decision.
The Omicron XBB.1.5-adapted monovalent COVID-19 vaccines developed by Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX), and Moderna (NASDAQ:MRNA) are currently under FDA review as the U.S. prepares for a fall immunization drive.
Last month, Novavax (NASDAQ:NVAX), the maker of Nuvaxovid COVID, shot said its global regulatory submissions for the COVID-19 vaccine, adjusted for the XBB. 1.5 were ongoing.

More on Pfizer, BioNTech, etc.

Pfizer: The Floor To This Decline Remains To Be Seen
BioNTech: Not Just Another Jab In The Arm
Pfizer, Moderna And COVID Vaccine Patents: Implications Of Legal Cases
Pfizer: Searching For A Bottom
Moderna: Buy Before The Fall Covid-19 Wave
Pfizer Stock: The Right Time To Buy Now (Technical Analysis)
Novavax Q2 2023 Earnings Review: Still Drinking At The Last Chance Saloon
Pfizer: Doubling Down Buying Opportunity Is Here
Moderna says COVID shot strongly responded to Pirola variant
Pfizer, BioNTech granted EU nod for new Omicron-adapted COVID shot
Pfizer sees Q4 restart at tornado damaged N.C. facility